Amgen 2011 Annual Report Download - page 10

Download and view the complete annual report

Please find page 10 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 184

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184

Amgen 2011 Annual Report
From our innovative therapies to our growing
network of partnerships, we strive to expand
support of and the options available to patients
with serious illnesses. In 2011, we made good
on that core commitment with new product
approvals (see page 7), important collaborations,
and signifi cant programs.
Partnerships to Help and Educate Patients
• While battling cancer is hard enough, some
cancer treatments heighten the risk of serious
infections by decreasing white blood cell counts.
Thousands of patients are hospitalized in the United
States for chemotherapy-related infections every
year. Amgen hopes to help lower that toll through
a partnership with the CDC Foundation, a nonprofi t
organization that connects the Centers for Disease
Control and Prevention with the private sector to
build public health programs. In 2011, Amgen
provided funding and oncology expertise to the
CDC Foundation in support of the CDC’s Preventing
Infections in Cancer Patients program, which
advises patients and caregivers on how to assess
and help lower infection risk.
• Amgen became a founding sponsor of ON THE LINE,
a new prostate cancer awareness program in the
United States that harnesses the influence of
sports celebrities to help men become more
aware of their risk factors and their options for
diagnosis and treatment.
• Amgen’s Breakaway from Cancer®
initiative launched an enhanced website,
www.breakawayfromcancer.com, that gives cancer
patients, survivors, and caregivers essential resources
they need to help them maneuver through today’s
complicated maze of online information.
• Inspired by a 2010 survey that found that
patients with osteoporosis are more concerned
than physicians realized when it comes to learning
about risks and getting advice on managing their
disease, the International Osteoporosis Foundation
started OsteoLink, the first social network for
people in Europe and Australia with osteoporosis.
Amgen and GlaxoSmithKline are lead co-sponsors
of the new network, which makes it easier for
patients, family members, and caregivers to share
experiences and insights, fi nd credible information
about osteoporosis, and learn from one another.
• Award-winning actress Blythe Danner teamed up
with Amgen to launch Act 2 Reduce Fractures™
,
a campaign in the United States to promote
Prolia® (denosumab) as an option for treating
osteoporosis in women after menopause who
are at high risk for fracture.
• To help patients, consumers, and healthcare
professionals in their discussions about the safe
use of medicines, Amgen has launched a new
section on Amgen.com titled Information about
Medicine Safety.
Putting Patients First with
Our Products, Programs, and Partnerships
On Course with Phil—Helping Others Manage Psoriatic Arthritis
While Phil Mickelson is accustomed to meeting challenges on the golf course, he wasn’t sure how to deal with the
joint stiffness and severe pain that threatened his golf career two years ago. “It was so intense, I could hardly get
out of bed,” Phil recalls. “It was really scary. I saw a rheumatologist and got diagnosed with psoriatic arthritis. I was
lucky to fi nd out it was very treatable.”
Phil’s treatment program includes Enbrel® (etanercept), which has helped improve his overall health so he can
return to the things that matter most to him. But remembering the uncertainty he faced when his symptoms fi rst
struck, he decided to tell about his experience. “I want to motivate and empower others with chronic infl ammatory
joint and skin conditions to take action,” Phil says. In partnership with Amgen and Pfi zer, Phil launched On Course
with Phil, a disease education website, which also features Be Joint Smart, a new educational effort sponsored
by the Arthritis Foundation and the National Psoriasis Foundation.
At Amgen, our work revolves around our mission to serve patients. Amgen therapeutics have reached
more than 22 million people around the globe in their fi ght against many diseases, including cancer,
kidney disease, rheumatoid arthritis, and bone disease.
8